Risk factor
Good trading liquidity
Profitability factor
Very favourable analyst view
About
Haisco Pharmaceutical Group Co., Ltd., together with its subsidiaries, develops, produces, and sells drugs in China. The company offers small-volume injections, freeze-dried powder injections, powder injections, large-volume injections, active pharmaceutical ingredient, etc. for various therapeutic fields, including anti-infective, digestive system, blood system, nervous system, parenteral nutrition, antibiotics, first aid, anesthetics, and tumor; and tablets, capsules, granules, and ointments in the fields of cardiovascular, anti-infection, digestive system, CNS system, diabetes, and hepatic diseases. The company was formerly known as Xizang Haisco Pharmaceutical Group Co., Ltd. and changed its name to Haisco Pharmaceutical Group Co., Ltd. in March 2016. Haisco Pharmaceutical Group Co., Ltd. was founded in 2000 and is based in Shannan, China.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBI
Target Price
The average target price of 002653.SZ is 99 and suggests 95% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc